Literature DB >> 30831192

Impaired development of neocortical circuits contributes to the neurological alterations in DYRK1A haploinsufficiency syndrome.

Juan Arranz1, Elisa Balducci1, Krisztina Arató2, Gentzane Sánchez-Elexpuru3, Sònia Najas4, Alberto Parras5, Elena Rebollo4, Isabel Pijuan1, Ionas Erb6, Gaetano Verde6, Ignasi Sahun7, Maria J Barallobre1, José J Lucas8, Marina P Sánchez3, Susana de la Luna9, Maria L Arbonés10.   

Abstract

Autism spectrum disorders are early onset neurodevelopmental disorders characterized by deficits in social communication and restricted repetitive behaviors, yet they are quite heterogeneous in terms of their genetic basis and phenotypic manifestations. Recently, de novo pathogenic mutations in DYRK1A, a chromosome 21 gene associated to neuropathological traits of Down syndrome, have been identified in patients presenting a recognizable syndrome included in the autism spectrum. These mutations produce DYRK1A kinases with partial or complete absence of the catalytic domain, or they represent missense mutations located within this domain. Here, we undertook an extensive biochemical characterization of the DYRK1A missense mutations reported to date and show that most of them, but not all, result in enzymatically dead DYRK1A proteins. We also show that haploinsufficient Dyrk1a+/- mutant mice mirror the neurological traits associated with the human pathology, such as defective social interactions, stereotypic behaviors and epileptic activity. These mutant mice present altered proportions of excitatory and inhibitory neocortical neurons and synapses. Moreover, we provide evidence that alterations in the production of cortical excitatory neurons are contributing to these defects. Indeed, by the end of the neurogenic period, the expression of developmental regulated genes involved in neuron differentiation and/or activity is altered. Therefore, our data indicate that altered neocortical neurogenesis could critically affect the formation of cortical circuits, thereby contributing to the neuropathological changes in DYRK1A haploinsufficiency syndrome.
Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Autism spectrum disorder; Cerebral cortex; DYRK1A mutations; Epilepsy; Neurodevelopment; Transcriptome

Mesh:

Substances:

Year:  2019        PMID: 30831192      PMCID: PMC6753933          DOI: 10.1016/j.nbd.2019.02.022

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  70 in total

1.  DYRK1A accumulates in splicing speckles through a novel targeting signal and induces speckle disassembly.

Authors:  Monica Alvarez; Xavier Estivill; Susana de la Luna
Journal:  J Cell Sci       Date:  2003-06-10       Impact factor: 5.285

Review 2.  Interneurons of the neocortical inhibitory system.

Authors:  Henry Markram; Maria Toledo-Rodriguez; Yun Wang; Anirudh Gupta; Gilad Silberberg; Caizhi Wu
Journal:  Nat Rev Neurosci       Date:  2004-10       Impact factor: 34.870

3.  Activation-loop autophosphorylation is mediated by a novel transitional intermediate form of DYRKs.

Authors:  Pamela A Lochhead; Gary Sibbet; Nick Morrice; Vaughn Cleghon
Journal:  Cell       Date:  2005-06-17       Impact factor: 41.582

Review 4.  Neuronal subtype specification in the cerebral cortex.

Authors:  Bradley J Molyneaux; Paola Arlotta; Joao R L Menezes; Jeffrey D Macklis
Journal:  Nat Rev Neurosci       Date:  2007-06       Impact factor: 34.870

5.  Specificity determinants of substrate recognition by the protein kinase DYRK1A.

Authors:  S Himpel; W Tegge; R Frank; S Leder; H G Joost; W Becker
Journal:  J Biol Chem       Date:  2000-01-28       Impact factor: 5.157

6.  Alterations in the phenotype of neocortical pyramidal cells in the Dyrk1A+/- mouse.

Authors:  R Benavides-Piccione; M Dierssen; I Ballesteros-Yáñez; M Martínez de Lagrán; M L Arbonés; V Fotaki; J DeFelipe; G N Elston
Journal:  Neurobiol Dis       Date:  2005-10       Impact factor: 5.996

7.  Identification of the autophosphorylation sites and characterization of their effects in the protein kinase DYRK1A.

Authors:  S Himpel; P Panzer; K Eirmbter; H Czajkowska; M Sayed; L C Packman; T Blundell; H Kentrup; J Grötzinger; H G Joost; W Becker
Journal:  Biochem J       Date:  2001-11-01       Impact factor: 3.857

8.  Evolutionary constraints associated with functional specificity of the CMGC protein kinases MAPK, CDK, GSK, SRPK, DYRK, and CK2alpha.

Authors:  Natarajan Kannan; Andrew F Neuwald
Journal:  Protein Sci       Date:  2004-08       Impact factor: 6.725

9.  Haploinsufficiency of Dyrk1A in mice leads to specific alterations in the development and regulation of motor activity.

Authors:  V Fotaki; M Martínez De Lagrán; X Estivill; M Arbonés; M Dierssen
Journal:  Behav Neurosci       Date:  2004-08       Impact factor: 1.912

10.  Dyrk1A haploinsufficiency affects viability and causes developmental delay and abnormal brain morphology in mice.

Authors:  Vassiliki Fotaki; Mara Dierssen; Soledad Alcántara; Salvador Martínez; Eulàlia Martí; Caty Casas; Joana Visa; Eduardo Soriano; Xavier Estivill; Maria L Arbonés
Journal:  Mol Cell Biol       Date:  2002-09       Impact factor: 4.272

View more
  11 in total

1.  A Multiplex Human Pluripotent Stem Cell Platform Defines Molecular and Functional Subclasses of Autism-Related Genes.

Authors:  Gustav Y Cederquist; Jason Tchieu; Scott J Callahan; Kiran Ramnarine; Sean Ryan; Chao Zhang; Chelsea Rittenhouse; Nadja Zeltner; Sun Young Chung; Ting Zhou; Shuibing Chen; Doron Betel; Richard M White; Mark Tomishima; Lorenz Studer
Journal:  Cell Stem Cell       Date:  2020-07-02       Impact factor: 24.633

Review 2.  A perspective on molecular signalling dysfunction, its clinical relevance and therapeutics in autism spectrum disorder.

Authors:  Sushmitha S Purushotham; Neeharika M N Reddy; Michelle Ninochka D'Souza; Nilpawan Roy Choudhury; Anusa Ganguly; Niharika Gopalakrishna; Ravi Muddashetty; James P Clement
Journal:  Exp Brain Res       Date:  2022-09-05       Impact factor: 2.064

3.  Social motivation a relative strength in DYRK1A syndrome on a background of significant speech and language impairments.

Authors:  Lottie D Morison; Ruth O Braden; David J Amor; Amanda Brignell; Bregje W M van Bon; Angela T Morgan
Journal:  Eur J Hum Genet       Date:  2022-04-18       Impact factor: 5.351

4.  Integrative approach to interpret DYRK1A variants, leading to a frequent neurodevelopmental disorder.

Authors:  Jérémie Courraud; Eric Chater-Diehl; Benjamin Durand; Marie Vincent; Maria Del Mar Muniz Moreno; Imene Boujelbene; Nathalie Drouot; Loréline Genschik; Elise Schaefer; Mathilde Nizon; Bénédicte Gerard; Marc Abramowicz; Benjamin Cogné; Lucas Bronicki; Lydie Burglen; Magalie Barth; Perrine Charles; Estelle Colin; Christine Coubes; Albert David; Bruno Delobel; Florence Demurger; Sandrine Passemard; Anne-Sophie Denommé; Laurence Faivre; Claire Feger; Mélanie Fradin; Christine Francannet; David Genevieve; Alice Goldenberg; Anne-Marie Guerrot; Bertrand Isidor; Katrine M Johannesen; Boris Keren; Maria Kibæk; Paul Kuentz; Michèle Mathieu-Dramard; Bénédicte Demeer; Julia Metreau; Rikke Steensbjerre Møller; Sébastien Moutton; Laurent Pasquier; Kristina Pilekær Sørensen; Laurence Perrin; Mathilde Renaud; Pascale Saugier; Marlène Rio; Joane Svane; Julien Thevenon; Frédéric Tran Mau Them; Cathrine Elisabeth Tronhjem; Antonio Vitobello; Valérie Layet; Stéphane Auvin; Khaoula Khachnaoui; Marie-Christine Birling; Séverine Drunat; Allan Bayat; Christèle Dubourg; Salima El Chehadeh; Christina Fagerberg; Cyril Mignot; Michel Guipponi; Thierry Bienvenu; Yann Herault; Julie Thompson; Marjolaine Willems; Jean-Louis Mandel; Rosanna Weksberg; Amélie Piton
Journal:  Genet Med       Date:  2021-08-03       Impact factor: 8.822

5.  Dyrk1a Mutations Cause Undergrowth of Cortical Pyramidal Neurons via Dysregulated Growth Factor Signaling.

Authors:  Jenna A Levy; Christy W LaFlamme; George Tsaprailis; Gogce Crynen; Damon T Page
Journal:  Biol Psychiatry       Date:  2021-04-08       Impact factor: 12.810

6.  A novel de novo heterozygous DYRK1A mutation causes complete loss of DYRK1A function and developmental delay.

Authors:  Kyu-Sun Lee; Miri Choi; Dae-Woo Kwon; Doyoun Kim; Jong-Moon Choi; Ae-Kyeong Kim; Youngwook Ham; Sang-Bae Han; Sungchan Cho; Chong Kun Cheon
Journal:  Sci Rep       Date:  2020-06-17       Impact factor: 4.379

7.  The nuclear interactome of DYRK1A reveals a functional role in DNA damage repair.

Authors:  Steven E Guard; Zachary C Poss; Christopher C Ebmeier; Maria Pagratis; Helen Simpson; Dylan J Taatjes; William M Old
Journal:  Sci Rep       Date:  2019-04-25       Impact factor: 4.379

8.  DYRK1A-related intellectual disability: a syndrome associated with congenital anomalies of the kidney and urinary tract.

Authors:  Alexandria T M Blackburn; Nasim Bekheirnia; Vanessa C Uma; Mark E Corkins; Yuxiao Xu; Jill A Rosenfeld; Matthew N Bainbridge; Yaping Yang; Pengfei Liu; Suneeta Madan-Khetarpal; Mauricio R Delgado; Louanne Hudgins; Ian Krantz; David Rodriguez-Buritica; Patricia G Wheeler; Lihadh Al-Gazali; Aisha Mohamed Saeed Mohamed Al Shamsi; Natalia Gomez-Ospina; Hsiao-Tuan Chao; Ghayda M Mirzaa; Angela E Scheuerle; Mary K Kukolich; Fernando Scaglia; Christine Eng; Helen Rankin Willsey; Michael C Braun; Dolores J Lamb; Rachel K Miller; Mir Reza Bekheirnia
Journal:  Genet Med       Date:  2019-07-02       Impact factor: 8.822

Review 9.  Dyrk1a from Gene Function in Development and Physiology to Dosage Correction across Life Span in Down Syndrome.

Authors:  Helin Atas-Ozcan; Véronique Brault; Arnaud Duchon; Yann Herault
Journal:  Genes (Basel)       Date:  2021-11-20       Impact factor: 4.096

10.  Dyrk1a gene dosage in glutamatergic neurons has key effects in cognitive deficits observed in mouse models of MRD7 and Down syndrome.

Authors:  Véronique Brault; Thu Lan Nguyen; Javier Flores-Gutiérrez; Giovanni Iacono; Marie-Christine Birling; Valérie Lalanne; Hamid Meziane; Antigoni Manousopoulou; Guillaume Pavlovic; Loïc Lindner; Mohammed Selloum; Tania Sorg; Eugene Yu; Spiros D Garbis; Yann Hérault
Journal:  PLoS Genet       Date:  2021-09-29       Impact factor: 5.917

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.